These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9696434)

  • 21. [Relationships between magnesium and parathyroid hormone metabolism in healthy subjects, patients with chronic kidney failure and permanent dialysis patients].
    Samizadeh A; Wessels F; Losse H
    Verh Dtsch Ges Inn Med; 1978; (84):1294-7. PubMed ID: 741952
    [No Abstract]   [Full Text] [Related]  

  • 22. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between dialysate oxidized protein and peritoneal membrane transport properties in patients on peritoneal dialysis.
    Latcha S; Hong S; Gibbons N; Kohn N; Mattana J
    Nephrol Dial Transplant; 2008 Oct; 23(10):3295-301. PubMed ID: 18443211
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An analysis of the effectiveness and benefits of peritoneal dialysis and haemodialysis using Nigerian made PD fluids.
    Arogundade FA; Ishola DA; Sanusi AA; Akinsola A
    Afr J Med Med Sci; 2005 Sep; 34(3):227-33. PubMed ID: 16749353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Magnesium in chronic kidney disease: unanswered questions.
    Spiegel DM
    Blood Purif; 2011; 31(1-3):172-6. PubMed ID: 21228586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The impact of changes in levels of calcium, phosphate and magnesium during hemodialysis on autonomic system reactivity as measured by heart rate variability analysis].
    Buda S; Stompór T; Sułowicz W; Kopeć J; Szymczakiewicz-Multanowska A; Janion M
    Przegl Lek; 2000; 57(6):340-5. PubMed ID: 11107869
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones.
    Grzegorzewska AE; Młot M
    Rocz Akad Med Bialymst; 2004; 49():193-6. PubMed ID: 15631342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of dialytic modalities on clinical outcomes in ESRD patients with familial Mediterranean fever.
    Sahin S; Sahin GM; Ergin H; Kantarci G
    Ren Fail; 2007; 29(3):315-9. PubMed ID: 17497446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulmonary function in renal transplant recipients and end-stage renal disease patients undergoing maintenance dialysis.
    Karacan O; Tutal E; Colak T; Sezer S; Eyüboğlu FO; Haberal M
    Transplant Proc; 2006 Mar; 38(2):396-400. PubMed ID: 16549130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.
    Iglesias P; Díez JJ; Fernández-Reyes MJ; Méndez J; Bajo MA; Aguilera A; Selgas R
    Clin Endocrinol (Oxf); 2004 Jun; 60(6):741-9. PubMed ID: 15163339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peritoneal dialysis is the therapy of choice for end-stage renal disease patients with hereditary clotting disorders.
    Bajo MA; del Peso G; Jiménez V; Aguilera A; Villar A; Jiménez C; Selgas R
    Adv Perit Dial; 2000; 16():170-3. PubMed ID: 11045286
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Silicon metabolism: the basic facts in renal failure.
    Berlyne G; Dudek E; Adler AJ; Rubin JE; Seidman M
    Kidney Int Suppl; 1985 Dec; 17():S175-7. PubMed ID: 3867790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of a patient with end-stage renal disease with Rituximab: pharmacokinetic evaluation suggests Rituximab is not eliminated by hemodialysis.
    Jillella AP; Dainer PM; Kallab AM; Ustun C
    Am J Hematol; 2002 Nov; 71(3):219-22. PubMed ID: 12410580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association between body mass index and body fat in chronic kidney disease stages 3 to 5, hemodialysis, and peritoneal dialysis patients.
    Leinig C; Pecoits-Filho R; Nascimento MM; Gonçalves S; Riella MC; Martins C
    J Ren Nutr; 2008 Sep; 18(5):424-9. PubMed ID: 18721737
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
    Siu YP; Leung KT; Tong MK; Kwan TH
    Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuropeptide Y and markers of osteoblast activity in dialysis patients: a cross-sectional study.
    Panuccio V; Cutrupi S; Pizzini P; Mallamaci F; Tripepi G; Zoccali C
    Am J Kidney Dis; 2007 Dec; 50(6):1001-8. PubMed ID: 18037100
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oxidative stress in chronic renal failure patients treated by peritoneal dialysis.
    Al-Hashimi AF; Mohammed FH; Al-Khazragi AS
    Saudi Med J; 2004 Sep; 25(9):1186-92. PubMed ID: 15448763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Advanced glycation end products in renal failure.
    Thornalley PJ
    J Ren Nutr; 2006 Jul; 16(3):178-84. PubMed ID: 16825015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intracellular magnesium depletion in chronic renal failure.
    Lim P; Dong S; Khoo OT
    N Engl J Med; 1969 May; 280(18):981-4. PubMed ID: 5777924
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.